NIH and India partner to develop low-cost health-care technologies

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH), and the Department of Biotechnology (DBT) of the Ministry of Science and Technology of the Republic of India, have entered into a bilateral agreement to develop low-cost health-care technologies aimed at the medically underserved.

The agreement is based on a shared commitment to improve the health and well-being of the people of both countries by encouraging collaborations and cooperation on the development of diagnostic and therapeutic medical technologies that are inexpensive and operate at the initial point of physician contact, or point of care.

"We are very pleased to officially establish this groundbreaking effort between NIH/NIBIB and the Department of Biotechnology," said NIBIB director Roderic I. Pettigrew, Ph.D., M.D. "This agreement will create a working partnership designed to help address global health disparities by encouraging the development of improved methods and technologies to diagnose and treat illness and injury across geographic and economic borders."

Areas of cooperation outlined in the agreement include low-cost innovations in X-ray technology; nanotechnology-based biosensors; point-of-care diagnostic technologies; telehealth and telecommunication technologies; and neonatal health technologies. The disease areas and conditions likely to be affected by the successful development of the technologies are infectious diseases, cardiovascular disease, liver disease, trauma and injury, and conditions associated with infant mortality.

"Developing low-cost health technologies that are unique in design to be affordable and useable in disease prevention and management is a high priority in India," said Maharaj Bhan, M.D., DBT director. "The partnership with NIH, and through them, with U.S. institutions, is critical for us to make progress. We are excited about this agreement with NIH to bring multiple disciplines and teams together to find innovative solutions."

As part of the agreement, NIBIB and the DBT will encourage workshops and meetings to share experiences and scientific information; link appropriate centers of excellence and institutes; engage in bilateral cooperation on the assessment and application of new diagnostic technologies; and generate collaboration among scientists and engineers in the conduct of research, research training, and technology development. The agencies will facilitate and share each other's efforts in research and development through regular interactions between scientists, and will work towards mutual, annual goals.

The signing of the Agreement on Science and Technology took place during a recent visit to the Ministry of Science and Technology in New Delhi, India.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), a component of the National Institutes of Health, U.S. Department of Health and Human Services, is dedicated to improving human health through the integration of the physical and biological sciences. The research agenda of the NIBIB seeks to dramatically advance the Nation's health by improving the detection, management, understanding, and ultimately, the prevention of disease. Additional information and publications are available at www.nibib.nih.gov.

The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose